SAMOH aims to provide healthier and
happier life of mankind.
CEO Message
We welcome your visit to
our website with great pleasure.

SAMOH Pharm/SAMOH Farmachem were established in 1983 with a mission to provide pharmaceutical products for enhancement in national health and quality of life. For more than 39 years, SAMOH has been striving for the advancement in pharmaceutical and healthcare industry as well as for better health of humanity.

With accumulated experiences and networks, SAMOH has been expending business from pharmaceutical ingredients to various areas, including veterinary pharmaceuticals, diagnostics, functional foods and cosmetics.

In order to supply high quality bulk pharmaceutical ingredients for both domestic and international customers, SAMOH established a Siheung plant in 1999 which has been GMP(BGMP)-certified by Korea Food and Drug Administration (KFDA)in 2001. SAMOH R&D center was established in 2001 to strengthen our development and production competitiveness.

SAMOH manufactures active pharmaceutical ingredients (APIs) including aceclofenac, Levodropropizine, Levosulpiride, Rebamipide, Tiropramide HCl. In addition to manufacturing APIs, SAMOH distribute various high-quality APIs imported from prominent producers through our global networks.

Through our trusted worldwide networks of renowned pharmaceutical companies, SAMOH Farmachem provide one-stop pharmaceutical solution for both domestic and international pharmaceutical companies including consulting, import/export service, licensing-in and out, and technology transfers services on pharmaceutical ingredients and finished dosage forms (FDFs).

In addition, SAMOH Pharm / SAMOH Farmachem have been specialized in marketing and sales of orphan drugs. Although orphan drugs are not well-known to public yet, we seek our endeavor would contribute to thriving domestic pharmaceutical market as well as improvement in national health.

Following fast-changing global pharmaceutical industry, all of us at SAMOH will take active initiatives in introducing new trends and technologies into domestic market and in managing global market intelligence, such as opening annual symposium with our global partners. Through our constant development of greater and safer new products, we will strive for prosperous future and improvement in national health.
Thank you very much.

  • J. S. Oh, Chairman
  • S. S. Oh, President